Notice of coming into force for Australia of Article 31bis of the Agreement on Trade- Related Aspects of Intellectual Property Rights

Overview

The Intellectual Property Laws Amendment Act 2015 was enacted to address certain gaps in Australia's intellectual property framework, ensuring compliance with international trade agreements. Specifically, the Act was introduced to implement Article 31bis of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which was established under the Marrakesh Agreement. This legislative amendment was necessary to align Australia's domestic laws with its international obligations under the World Trade Organization. The policy objective of the Act is to provide a legal framework that allows for the issuance of compulsory licenses in certain circumstances, particularly in cases of public health emergencies, thereby balancing the rights of patent holders with the need to ensure access to essential medicines. The Act was passed by the Parliament of Australia and came into force for Australia on 23 January 2017, as announced by Arthur Sinodinos, the Minister for Industry, Innovation and Science.

Scope and Application

The Intellectual Property Laws Amendment Act 2015, specifically concerning the implementation of Article 31bis of the Agreement on Trade-Related Aspects of Intellectual Property Rights, applies to all entities and persons within Australia, including but not limited to businesses, educational institutions, and individual inventors, who are engaged in activities related to intellectual property. This legislation aligns Australia with international obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights, which is an integral part of the World Trade Organization. The Act extends its jurisdictional reach across the entire nation, ensuring compliance with international standards regarding the use of compulsory licensing in certain circumstances, particularly in cases of public health emergencies. While the Act does not explicitly state exclusions or thresholds, it is understood that its application would be subject to the specific conditions and requirements outlined in the broader framework of the Agreement. Subordinate instruments or regulations may further define the implementation details, ensuring a clear and consistent application of the legislation across different sectors and industries.

Key Provisions

The primary operative sections of this notifiable instrument (sections 1-3) announce the commencement of Article 31bis of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for Australia. This Article allows for the issuance of compulsory licenses in certain circumstances to address public health emergencies, particularly relating to pandemics. Specifically, it permits the Australian government to authorise the manufacture and use of patented medicines without the consent of the patent holder under specific conditions, ensuring access to essential medications during public health crises (section 2). The obligations and requirements imposed by this legislation are primarily administrative and procedural. The government must identify a public health emergency that justifies the use of compulsory licensing and must consider the impact on the patent holder and the necessity of the measure to address the emergency. The compulsory licensing provisions must be exercised in a manner that is consistent with the principles of the TRIPS Agreement, ensuring that such measures are exceptional and do not unreasonably conflict with normal exploitation of the patent or create unwarranted prejudice to the legitimate interests of the patent holder (section 3). In terms of consequences, the notifiable instrument itself does not outline specific offences or penalties for breach. However, any misuse or abuse of the compulsory licensing provisions could lead to legal challenges or disputes under both domestic and international intellectual property laws. The TRIPS Agreement provides a framework for resolving such disputes, and any breaches of the agreement’s provisions could result in trade sanctions or other measures under international trade law. The primary focus of the legislation is to ensure that the compulsory licensing provisions are used judiciously and in the public interest, rather than to impose direct penalties for their misuse.